NCT05028504 - A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Gynecological Cancer

Interventions

DRUG

Penpulimab

Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

DRUG

Anlotinib

A multi-target receptor tyrosine kinase inhibitor

Trial Locations (6)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

510080

RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangdong

610000

RECRUITING

Sicchuan cancer hospital, Chengdu

Unknown

RECRUITING

The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei

NOT_YET_RECRUITING

Shaanxi Provincial Cancer Hospital, Xi’an

RECRUITING

Shaanxi Provincial People's Hospital, Xi’an

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER